Healthcare - Press Releases

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The globalnitrile gloves marketsize is estimated to grow by USD 3.54 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.8% during the forecast period. Rising concerns about hygiene and safety regarding healthcare-associated infectionsis driving market growth,with a trend towardsincreasing preference for biodegradable and powder-free nitrile gloves. However,volatile raw material prices and currency fluctuations poses a challenge. Key market players include 3M Co., Adenna LLC, AMMEX Corp., Ansell Ltd., Atlantic Safety Products Inc., Cardinal Health Inc., Diamond Gloves, Dolphin Products Inc., Dynarex Corp., Globus Shetland Ltd., Hartalega Holdings Berhad, Hebei Aihede Protective Products Co. Ltd., Honeywell International Inc., Hongray Group, HYGECO International SA, Just Gloves, Kanam Latex Industries Pvt. Ltd, Kimberly Clark Corp., Kossan Rubber Industries Bhd, and McKesson Corp..

A mind-numbing bore fest or a wake-up call? The nine-hour runtime exposes the staggering impact of smartphone overuse on 84% of teens, highlighting issues such as ADHD, depression, and more.This film mirrors the average time teenagers spend doom-scrolling, shedding light on the urgent need for change.

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ --On the eve of theArab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration.

NEW YORK, Jan. 26, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The globalmedical gas blenders marketsize is estimated to grow by USD 582 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.42% during the forecast period. Growing geriatric population and rising prevalence of chronic diseasesis driving market growth,with a trend towardsincreasing use of respiratory gas blenders in NICUs. However,stringent regulations on design and manufacturing of medical gas blenders poses a challenge. Key market players include Medin Medical Innovations GmbH, HEYER Medical AG, EKU Electronics, Armstrong Medical, Becton, Dickinson and Company, Farstar (Wuxi) Medical Equipment, Dameca, Flow-meter S.p.A, Smiths Medical, Heyer Aerotech GmbH, DEHAS Medical Systems GmbH, ESAB Corp., Genstar Technologies Co. Inc., Guangdong Pigeon Medical Apparatus Co. Ltd., HVS Oliver Hornla GmbH and Co. KG, Inspiration Healthcare Group Plc., MCQ Instruments, Ningbo David Medical Device Co. Ltd., Precision Medical Inc., S S Technomed P Ltd.

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global healthcare services marketsize is estimated to grow by USD 6.26 trillion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.73% during the forecast period. Increasing prevalence of chronic diseasesis driving market growth,with a trend towardsrise in adoption of telemedicine in healthcare sector. However,increasing healthcare costs poses a challenge. Key market players include Apollo Hospitals Enterprise Ltd, athenahealth Inc., Community Health Systems Inc., CVS Health Corp., DaVita Inc., Dr Lal PathLabs Ltd., Expedient Healthcare Marketing Pvt. Ltd., Fresenius Medical Care AG and Co. KGaA, Genesis Healthcare Inc., iHealth Labs Inc., Max Healthcare Institute Ltd, Mayo Foundation for Medical Education and Research, McKesson Corp., OMH HealthEdge Holdings LLC, Optum Inc., Quest Diagnostics Inc., Sonic Healthcare Ltd., Universal Health Services Inc., and West Suffolk NHS Foundation Trust.

SACRAMENTO, Calif., Jan. 24, 2025 /PRNewswire/ --The California Fire Foundation, in partnership with GovernorGavin Newsom, have announced "California Rises," a bold new phase of wildfire recovery and resilience, providing relief and grants to communities devastated by catastrophic wildfires in the Los Angeles-area.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis. The strategic combination of drugs such as gumokimab and ebronucimab (PCSK9) to address the differentiated treatment needs of psoriasis has further enhanced the company's overall product synergy in the autoimmune disease field.

TAICHUNG, Jan. 26, 2025 /PRNewswire/ -- Since its inception in 2016, the China Medical University Hospital (CMUH) International Center has been dedicated to providing world-class healthcare to the people of Guam, delivering nearly 900 services to date. This partnership has extended beyond medical care, with CMUH's significant contributions during the COVID-19 pandemic. In 2020, the hospital worked closely with Taiwan's Ministry of Foreign Affairs to donate 200,000 face masks to Guam, a gesture for which Guam's government later issued a resolution of gratitude. Additionally, CMUH organized "humanitarian healthcare flights" for the people of Guam, further solidifying ties and contributing to the sister-city relationship between Taichung and Guam established in 2022. These efforts exemplify Taiwan's commitment to supporting global health, demonstrating the power of "medical diplomacy."

STOCKHOLM, Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease). This approval means that patients who have completed the biweekly initiation phase of 18 months have the option to transition to a once every four weeks 10 mg/kg dosing regimen.

STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) or mild dementia stage of disease in the U.S. (early Alzheimer's disease). This approval means that patients who have completed the biweekly initiation phase of 18 months have the option to transition to a once every four weeks 10 mg/kg dosing regimen.

Innovative Veterinary Practice Improvement Company Drives Veterinary Practice Efficiency, GreaterPatient Care, and Customer Loyalty with Cutting-Edge AI Enhancements

CLEVELAND, Jan. 24, 2025 /PRNewswire/ -- Standard Wellness Holdings, LLC ("Standard Wellness"), a multi-state, vertically integrated cannabis operator focused on improving quality of life through safe and easy access to cannabis, announces partnership with Miss Grass, a female-founded, community-driven brand, to distribute its line of premium THC products to Missouri.

PLEASANT GROVE, Utah, Jan. 24, 2025 /PRNewswire/ --In response to the devastating wildfires sweeping across California, dTERRA Healing Hands has taken swift action to support those affected. To date, the organization has sent 6,950 relief kits to the affected areas, which will be distributed by 134 dedicated Wellness Advocates.

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Revolutionary skin tightening is at your fingertips thanks to the innovative technology behind Quantum RF Skin Tightening by InMode. And plastic surgeon and NewBeauty Top Doctor, Elie Levine, MD of Plastic Surgery and Dermatology of NYC is one of the very first to offer true expertise in this exciting new device.

Recognizing nine student entrepreneurs for their innovative solutions

WASHINGTON, Jan. 24, 2025 /PRNewswire/ --

ST. PETERSBURG, Fla., Jan. 24, 2025 /PRNewswire/ -- Johnson PopeBokor Ruppel & Burns, LLP is excited to announce that Adam D. Kravatz has joined the firm as an associate in its Healthcare Practice Group, further solidifying the firm's reputation as a leader in delivering exceptional legal services to clients in Florida and beyond.

PITTSBURGH, Jan. 24, 2025 /PRNewswire/ -- "Cold water therapy can offer a lot of health benefits, but standard methods can be expensive and waste water and ice," said one of two inventors, fromDubbo, NSW, Australia, "so we invented the ICE RAIN. Our design would provide a more affordable and efficient alternative to traditional plunge pools and other means of engaging in cold plunge therapy."

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI, an oral, once-daily treatment for use in patients 12 years of age and older with WHIM syndrome.

Springbok's AI-Powered Muscle Analytics Is Advancing Precision Medicine, Elite Sports Performance, and Longevity on a Global Scale

LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI, an oral, once-daily treatment for use in patients 12 years of age and older with WHIM syndrome.

PITTSBURGH, Jan. 24, 2025 /PRNewswire/ -- "I'm a dentist and after years of treating people from all walks of life wanted to create an easy and effective way to treat tooth decay at a fraction of the cost of more conventional drill and fill methods," said an inventor, fromChambersburg, Pa., "so I invented THE SILVER SOLUTION. My design offers an alternative to brushing when on-the-go or away from home, could help improve a person's oral health, and from what I have seen in my practice using one of the active ingredients also control bacterial infections."